Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focusing on neurodegenerative diseases, will participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. The event will be held both virtually and in-person at the Lotte New York Palace Hotel.
Dr. Maria L. Maccecchini, Founder, President, and CEO of Annovis Bio, will deliver a company presentation on Tuesday, September 10, 2024, from 8:00 - 8:30 a.m. ET. She will also participate in a panel discussion on 'Non-amyloid Approaches in Alzheimer's Disease' on the same day from 2:00 - 3:00 p.m. ET, alongside representatives from Anavex Life Sciences Corp. and Longeveron Inc.
The presentation will cover Annovis' recent advancements and strategic direction, followed by a Q&A session. Attendees can schedule one-on-one meetings with Dr. Maccecchini through the conference portal or by contacting meetings@hcwco.com.
Annovis Bio (NYSE: ANVS), una compagnia farmaceutica in fase avanzata che si concentra su malattie neurodegenerative, parteciperà alla 26ª Conferenza Globale di Investimento Annuale H.C. Wainwright che si terrà dal 9 all'11 settembre 2024. L'evento si svolgerà sia in forma virtuale che di persona presso il Lotte New York Palace Hotel.
La Dr.ssa Maria L. Maccecchini, Fondatrice, Presidente e CEO di Annovis Bio, terrà una presentazione aziendale martedì 10 settembre 2024, dalle 8:00 alle 8:30 a.m. ET. Parteciparà anche a una discussione di panel su 'Approcci non amiloidi nella malattia di Alzheimer' lo stesso giorno dalle 2:00 alle 3:00 p.m. ET, insieme ai rappresentanti di Anavex Life Sciences Corp. e Longeveron Inc.
La presentazione tratterà i recenti progressi di Annovis e la direzione strategica, seguita da una sessione di domande e risposte. I partecipanti possono pianificare incontri individuali con la Dr.ssa Maccecchini tramite il portale della conferenza o contattando meetings@hcwco.com.
Annovis Bio (NYSE: ANVS), una empresa farmacéutica en etapa avanzada centrada en enfermedades neurodegenerativas, participará en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright que se llevará a cabo del 9 al 11 de septiembre de 2024. El evento se celebrará tanto de manera virtual como presencial en el Lotte New York Palace Hotel.
La Dra. Maria L. Maccecchini, fundadora, presidenta y CEO de Annovis Bio, presentará una presentación de la empresa el martes 10 de septiembre de 2024, de 8:00 a 8:30 a.m. ET. También participará en un panel de discusión sobre 'Enfoques no amiloides en la enfermedad de Alzheimer' el mismo día de 2:00 a 3:00 p.m. ET, junto a representantes de Anavex Life Sciences Corp. y Longeveron Inc.
La presentación cubrirá los recientes avances de Annovis y su dirección estratégica, seguida de una sesión de preguntas y respuestas. Los asistentes pueden programar reuniones uno a uno con la Dra. Maccecchini a través del portal de la conferencia o contactando a meetings@hcwco.com.
아노비스 바이오 (NYSE: ANVS), 신경퇴행성 질환에 중점을 둔 후기 단계 임상 약물 플랫폼 회사가 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 참여할 예정입니다. 이 행사는 2024년 9월 9일부터 11일까지 가상 및 대면으로 롯데 뉴욕 팰리스 호텔에서 열립니다.
아노비스 바이오의 설립자이자 대표, CEO인 마리아 L. 마체치니 박사가 2024년 9월 10일 화요일 오전 8:00 - 8:30 ET에 회사 발표를 진행할 예정입니다. 같은 날 오후 2:00 - 3:00 ET에 아나벡스 라이프 사이언스와 론지버론 주식회사의 대표들과 함께 '알츠하이머병의 비아밀로이드 접근법'에 대한 패널 토론에도 참석할 것입니다.
발표는 아노비스의 최근 발전과 전략적 방향을 다룰 예정이며, 질의응답 세션도 이어집니다. 참석자는 회의 포털을 통해 마체치니 박사와 일대일 미팅을 예약하거나 meetings@hcwco.com으로 연락할 수 있습니다.
Annovis Bio (NYSE: ANVS), une entreprise pharmaceutique en phase clinique avancée axée sur les maladies neurodégénératives, participera à la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright qui se tiendra du 9 au 11 septembre 2024. L'événement aura lieu à la fois virtuellement et en personne au Lotte New York Palace Hotel.
Dr. Maria L. Maccecchini, Fondatrice, Présidente et Directrice Générale d'Annovis Bio, donnera une présentation de l'entreprise le mardi 10 septembre 2024, de 8h00 à 8h30 ET. Elle participera également à une table ronde sur 'Approches non amyloïdes dans la maladie d'Alzheimer' le même jour de 14h00 à 15h00 ET, aux côtés de représentants d'Anavex Life Sciences Corp. et de Longeveron Inc.
La présentation couvrira les récents progrès d'Annovis et sa direction stratégique, suivie d'une session de questions et réponses. Les participants peuvent programmer des réunions individuelles avec Dr. Maccecchini via le portail de la conférence ou en contactant meetings@hcwco.com.
Annovis Bio (NYSE: ANVS), ein Unternehmen mit einer späten klinischen Medikamentenplattform, das sich auf neurodegenerative Erkrankungen konzentriert, wird an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright teilnehmen, die vom 9. bis 11. September 2024 stattfindet. Die Veranstaltung wird sowohl virtuell als auch persönlich im Lotte New York Palace Hotel abgehalten.
Dr. Maria L. Maccecchini, Gründerin, Präsidentin und CEO von Annovis Bio, wird am Dienstag, den 10. September 2024, von 8:00 bis 8:30 Uhr ET eine Präsentation des Unternehmens halten. Am selben Tag wird sie auch an einer Podiumsdiskussion über 'Nicht-Amyloid-Ansätze bei Alzheimer' teilnehmen, zusammen mit Vertretern von Anavex Life Sciences Corp. und Longeveron Inc.
Die Präsentation wird die jüngsten Fortschritte von Annovis sowie die strategische Ausrichtung abdecken, gefolgt von einer Frage- und Antwortsitzung. Teilnehmer können über das Konferenzportal Einzelgespräche mit Dr. Maccecchini planen oder meetings@hcwco.com kontaktieren.
- None.
- None.
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, held both virtually and in person at the Lotte New York Palace Hotel in New York City, September 9-11, 2024.
Event Details
Company Presentation:
- Date: Tuesday, September 10, 2024
- Time: 8:00 - 8:30 a.m. Eastern Time (ET)
Panel Participation:
- Topic: "Non-amyloid Approaches in Alzheimer’s Disease"
- Date: Tuesday, September 10, 2024
- Time: 2:00 - 3:00 p.m. ET
During the Company presentation, Dr. Maccecchini will provide an overview of Annovis’ recent advancements and strategic direction, followed by a Q&A session. In addition, Dr. Maccecchini will participate in a panel discussion focusing on innovative non-amyloid approaches in Alzheimer’s disease, featuring representatives from Annovis Bio (ANVS), Anavex Life Sciences Corp. (AVXL), and Longeveron Inc. (LGVN).
Please note that the presentation schedule is subject to change. Attendees are encouraged to check the conference agenda for the most current information.
To schedule a one-on-one meeting with Dr. Maccecchini, please use the conference portal or contact meetings@hcwco.com.
For more information, please visit the conference website.
About Annovis Bio, Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.Annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
IR@annovisbio.com
FAQ
When is Annovis Bio (ANVS) presenting at the H.C. Wainwright Global Investment Conference?
What panel is Annovis Bio (ANVS) participating in at the conference?
Who will be representing Annovis Bio (ANVS) at the H.C. Wainwright conference?
Where is the H.C. Wainwright 26th Annual Global Investment Conference being held?
How can investors schedule a meeting with Annovis Bio (ANVS) at the conference?
